Alembic Pharma Shares Gain Following USFDA Inspection Approval

Alembic Pharmaceuticals' share price surged 1% in early trade on April 30. This gain was fueled by the company receiving the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration for its oncology formulation facility located in Panelav.

Main News

The company's stock price rose by 1.05%, reaching Rs 888.45 at 09:20 AM on April 30. This followed the announcement that Alembic Pharma had received the EIR for its oncology formulation facility, which the USFDA inspected between October 7 and 8, 2024.

USFDA Inspection and EIR

Alembic Pharmaceuticals confirmed in its press release that the USFDA inspection at their Panelav-based oncology formulation facility (which includes injectable and oral solid formulations) was conducted in October 2024. The receipt of the EIR signifies the successful conclusion of the inspection without any significant issues raised.

New Manufacturing Facility at Pithampur

On April 26, Alembic Pharma announced the commissioning of a new manufacturing facility at Pithampur in Dhar District, Madhya Pradesh. This facility, designed to manufacture formulations, marks a significant expansion for the company.

Upcoming Board Meeting

The company has planned a Board of Directors meeting on May 6, 2025, to review and finalize the audited financial results for the quarter and full financial year ending March 31, 2025.

Additionally, the board will consider recommending a dividend on equity shares, if applicable, for the 2024-2025 financial year.

Market Performance

Despite the recent gains, Alembic Pharma's stock has faced some challenges. Over the past nine months, the share price has declined by 28%. The stock reached its 52-week high of Rs 1,296.15 on October 9, 2024, and its 52-week low of Rs 725.60 on March 3, 2025. Currently, the stock is trading 31.45% below its 52-week high and 22.44% above its 52-week low.

• Market capitalization: Rs 17,463.65 crore
• Stock price change (April 30, 2025): +1.05%

Summary

Alembic Pharma's stock was boosted due to the successful USFDA inspection of its oncology formulation facility in Panelav. Although the stock has faced significant volatility in the last year, the upcoming board meeting in May will provide further insights into the company's financial performance and potential dividend recommendations.